Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.36 |
| ▸ | LCK | P06239 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24323283 | 1.00 | LMNA (0.37) | LMNAHSP90AA1HSP90AB1LCKMAPK1 | |
| SCHEMBL22502015 | 0.90 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1LCK | |
| SCHEMBL22501987 | 0.85 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1LCK | |
| SCHEMBL31546947 | 0.85 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1LCK | |
| SCHEMBL24309477 | 0.84 | HSP90AA1 (0.36) | LMNAHSP90AA1HSP90AB1 | |
| SCHEMBL29566720 | 0.84 | HSP90AA1 (0.36) | LMNAHSP90AA1HSP90AB1 | |
| SCHEMBL22502018 | 0.83 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1LCK | |
| SCHEMBL24330502 | 0.81 | C5AR1 (0.31) | LMNALCK | |
| SCHEMBL29515265 | 0.81 | C5AR1 (0.31) | LMNALCK | |
| SCHEMBL24299011 | 0.81 | HSP90AA1 (0.38) | LMNAHSP90AA1HSP90AB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076622-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | LMNA 3793/4885HSP90AA1 1462/4885HSP90AB1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.